Necrosis in DU145 prostate cancer spheroids induces COX‐2/mPGES‐1‐derived PGE2 to promote tumor growth and to inhibit T cell activation
Open Access
- 28 March 2013
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 133 (7) , 1578-1588
Abstract
Cyclooxygenase (COX)‐2‐derived prostaglandin E2 (PGE2) supports the growth of a spectrum of cancers. The potential benefit of COX‐2‐inhibiting non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer treatment is however limited by their well‐known cardiovascular side‐effects. Therefore, targeting microsomal PGE synthase 1 (mPGES‐1), the downstream enzyme in the COX‐2‐dependent pathway of PGE2 production might be attractive, although conflicting data regarding a potential tumor‐supporting function of mPGES‐1 were reported. We determined the impact of mPGES‐1 in human DU145 prostate cancer cell growth. Surprisingly, knockdown of mPGES‐1 did not alter growth of DU145 monolayer cells, but efficiently inhibited the growth of DU145 multicellular tumor spheroids (MCTS). Opposed to MCTS, monolayer cells did not secrete PGE2 due to a lack of COX‐2 expression, which was induced during spheroid formation. Pharmacological inhibition of COX‐2 and mPGES‐1 supported the crucial role of PGE2 for growth of MCTS. The functionality of spheroid‐derived PGE2 was demonstrated by its ability to inhibit cytotoxic T cell activation. When investigating mechanisms of spheroid‐induced COX‐2 induction, we observed that among microenvironmental factors neither glucose deprivation, hypoxia nor tumor cell apoptosis enhanced COX‐2 expression. Interestingly, interfering with apoptosis in spheroids triggered a shift towards necrosis, thus augmenting COX‐2 expression. We went on to demonstrate that necrotic cells induced COX‐2 mRNA expression and PGE2 secretion from live tumor cells. In conclusion, necrosis‐dependent COX‐2 upregulation in MCTS promoted PGE2‐dependent tumor growth and inhibited activated cytotoxic T cells. Hence, blocking mPGES‐1 as a therapeutic option may be considered for COX‐2/mPGES‐1‐positive solid cancers.Keywords
This publication has 48 references indexed in Scilit:
- Apoptotic tumor cells induce IL‐27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicityEuropean Journal of Immunology, 2012
- Regulation of Immune Responses by Prostaglandin E2The Journal of Immunology, 2012
- Tumor Promotion via Injury- and Death-Induced InflammationImmunity, 2011
- M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 CellsThe Journal of Immunology, 2011
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- Apoptotic Cells Activate the “Phoenix Rising” Pathway to Promote Wound Healing and Tissue RegenerationScience Signaling, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- Signal pathways JNK and NF-κB, identified by global gene expression profiling, are involved in regulation of TNFα-induced mPGES-1 and COX-2 expression in gingival fibroblastsBMC Genomics, 2010
- Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cellsProceedings of the National Academy of Sciences, 2009
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instabilityCarcinogenesis, 2009